FOIA document: In 2007, US Ambassador Ralph Boyce was pleased that Abbott withdrew life saving drugs from market in ThailandSubmitted by James Love on 6. March 2010 - 17:26
In 2007, Thailand was involved in a dispute over the granting of compulsory licenses on medicines, including the patents used for Kaletra, an Abbott drug used in the treatment of AIDS. Kaletra is the brand name for a fixed dose combination of lopinavir and ritonavir (LPV/r) -- two drugs invented at Abbott on an NIH grant. In 2007, LPV/r was the preferred combination for protease inhibitor regimes used to treat AIDS.
KEI Research Note 2007:2 
(A PDF version of this is available here.)
Recent examples of the use of compulsory licenses on patents
KEI Research Note 2007:2
UNCTAD head Supachai Panitchpakdi will open up this December 16-19 event in Bangkok. The meeting is funded by the Federal Ministry for Economic Cooperation and Development (BMZ), Germany.
Event: Symposium on Flexibilities in International Intellectual Property Rules and Local Production of Medicines
Date: 16–19 December 2008
Location: Bangkok, Thailand
Venue: Conference Room of Arnoma Hotel
Worth reading first
March 8, 2007, Recent examples of the use of compulsory licensing of patents, revised March 31, 2007.
September 5, 2007. David Cronin for Intellectual Property Watch. EU Split Over Thai Effort to Obtain Cheapter Patented Drugs.
July 24, 2007. Bangkok Post. Thai Activists Attack Drug Ban.
Between November 2006 and January 2007, Thailand issued compulsory licenses for two AIDS drugs (efavirnz and the combination of lopinavir+ritonavir) and one antihypertension drug (clopidegrel). The pharmaceutical industry has vehemently objected to these compulsory licenses, and has sought the US government's assistance in the matter. Though USTR has been careful not to claim that the Thai government has violated the TRIPS Agreement, it did place Thailand on the 301 Report's Priority Watch List. Currently, the Thai government is in the process of deciding whe
Monday, 30 April 2007
"The sanctioning of countries for using legitimate and important flexibilities in the TRIPS agreement brings shame to all U.S. citizens who are increasingly seen in Thailand and elsewhere as bullies and hypocrites."
On Friday, March 16, KEI organized a briefing in the U.S. Capitol on Thailand’s recent compulsory licenses on three drugs; two for HIV/AIDS (Merck’s efavirenz (Stocrin) and Abbott’s lopinavir + ritonavir (Kaletra)) and one for heart disease (Sanofi’s clopidogrel (Plavix)). The briefing was sponsored by Senator Sherrod Brown and Congressman Tom Allen. Rep. Allen’s legislative assistant Todd Stein moderated a panel that included James Love of KEI, Robert Weissman of Essential Action, Dr.
Knowledge Ecology International: Q&A Session on Thai White Paper (Facts and Evidences on the 10 Burning Issues Related to the Government Use of Patents on Three Patented Essential Drugs in Thailand)
8 March 2007